Is there still a room for crizotinib in first-line setting in ALK-positive NSCLC patients?

20 / 39

Does PFS 1 mirror OS?
Ito - JTO 2017 * Gobbini – WCLC 2018 (Modified, Courtesy of Prof Besse)
Next generation ALK TKIs retain their efficacy regardless of the treatment setting considered